Intracavitary cisplatin therapy for pediatric malignancies

Pediatric Blood & Cancer
Howard M KatzensteinThomas A Olson

Abstract

Local control is essential for the successful treatment of pediatric solid tumors. Complete excision is often not possible and local control therapies are limited. Intracavitary cisplatin (IC-CDDP) may be utilized to supplement local control. The aim of the study was to determine the toxicity and efficacy of locally instilled intracavitary cisplatin in patients with recurrent tumors in closed body cavities. From 2001 to 2009, 12 patients (1-20 years) with recurrent or unresectable malignant tumors were treated with IC-CDDP. Nine had pulmonary lesions. Three patients had abdominal tumors. CDDP (200 mg/m(2)) was instilled by chest tube or Tenckhoff catheter. Patients were shifted every 15-30 min to allow distribution. After 4 hr, residual was drained by gravity. In 10/13 courses, sodium thiosulfate (STS) was administered to prevent nephrotoxicity. Three other patients received amifostine. Malignant pleural effusions resolved in 5/7 patients. This response was temporary in three patients. No patients had ascites prior to treatment. Three patients are alive and disease-free, 18 months, 4 years, and 6 years from treatment. They also had surgery and chemotherapy. Transient renal toxicity was noted in most patients. One patient, treat...Continue Reading

References

Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V W RuschM Markman
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F Ozols
Jul 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D E Brenner
Jan 1, 1985·Medical and Pediatric Oncology·M MarkmanS B Howell
Dec 1, 1982·Annals of Internal Medicine·S B HowellM Green
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M W BoyerW G Woods
Jul 13, 2002·Expert Review of Anticancer Therapy·M Markman
Dec 22, 2005·Gynecologic Oncology·Edward L Trimble, Michaele C Christian
Jan 6, 2006·The New England Journal of Medicine·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Jan 6, 2006·The New England Journal of Medicine·Stephen A Cannistra
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G RichardsDavid J Sugarbaker
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin GoreIgnace Vergote
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah K Armstrong, Mark F Brady
Oct 10, 2006·Gynecologic Oncology·Edward L Trimble, Ronald D Alvarez
Jul 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gautam RaoMace L Rothenberg

❮ Previous
Next ❯

Citations

Jul 24, 2014·Basic & Clinical Pharmacology & Toxicology·Badreldin H AliAbderrahim Nemmar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.